Pandion unveils new data to back up strategy of activating PD-1 to treat autoimmune diseases
Inhibiting the immune checkpoint protein PD-1 to combat tumors is the basis of several successful immuno-oncology drugs, including Merck’s Keytruda. But those drugs are known to raise the risk of some autoimmune diseases, such as colitis.